haNK

ImmunityBio is a vertically integrated biotechnology company developing next-generation therapies that bolster the immune system to defeat cancers and infectious diseases. The company's core technology revolves around its proprietary high-affinity Natural Killer (haNK) cell platform, which utilizes off-the-shelf NK cells engineered to express high-affinity CD16 receptors to enhance antibody-dependent cellular cytotoxicity (ADCC). ImmunityBio's lead product, Anktiva (N-803), is an IL-15 superagonist complex that has received FDA approval for the treatment of BCG-unresponsive non-muscle invasive bladder cancer. The company's pipeline integrates diverse modalities, including cell therapies, fusion proteins, and DNA/RNA vaccines, to create a multi-pronged approach to immunotherapy.